NOW ENROLLING 11 | 08 | 2022
PDO Screen
Patient-derived colorectal cancer organoid screening platform
Translate your in vitro pharmacology data from your lab to the clinic
The PDO screen uses state-of-the-art ATP-based cell viability assay on clinically relevant CRC Organoid models to help you access the therapeutic potential of your agent early in the drug development pipeline.
Benefit from:
- Clinical relevance with proven predictivity of patient response
- A unique framework to test toxicity in both tumors and matched normal organoids
- Physiologically relevant models that recapitulates key CRC driver mutations
- A cost-efficient screening service compared to stand-alone studies
- Quality assurance with frequent SNP checks and genomic characterizations
- Speed compared to in vivo studies
Features:
- ATP-based cell-viability assay with GR50 readouts
- 3D assay format with 96/384-well plate format
- Test up to 10 compounds in triplicates
- 14 models that capture the key CRC drivers
- 3 matched CRC-normal organoid pairs, 6 normal organoid lines
- 10-point dose-response curve/drug
- Representative of patient population heterogeneity with organoids derived from both primary and
Forecast a champion for your preclinical drug development pipeline.
Limited slots available!